M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
Peregrine reports Phase II study data for bavituximab plus docetaxel in advanced breast cancer patients
21 October 2009 - US-based biopharmaceutical company Peregrine Pharmaceuticals Inc (NASDAQ: PPHMD) reported today encouraging results from the Phase II study evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
Preliminary data at the end of the six...
If you want to view the full text of this story, you must first purchase archive retrieval credits.